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Abstract 
Current therapeutic strategies against glioblastoma (GBM) have failed to effectively 
prevent disease progression and recurrence. The role played by molecular imaging 
(MI) in the development of novel therapies has gained increasing traction in recent 
years. For the first time, leveraging expertise from an integrated multi-disciplinary 
authorship, we present herein a comprehensive evaluation of the state-of-the-art in 
GBM imaging and explore how advances facilitate emergence of new treatment 
options. We propose a novel next generation treatment paradigm based on the 
targeting of multiple „hallmarks of cancer‟ evolution of which will heavily rely on MI. 
 
Key words: glioblastoma (GBM), molecular imaging (MI), anti-GBM therapeutics 
  
Teaser: This review highlights the role played by molecular imaging in current and 
future GBM treatment approaches. 
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Introduction 
Based on estimations, 23 000 men and women (55% men) will be diagnosed with a 
primary brain or other nervous system malignancy this year in the United States with 
13 700 men and women to succumb to these diseases [1]. Glioma is the most 
common primary central nervous system (CNS) tumour. Widespread infiltration of 
surrounding tissue, the presence of necrotic tissue and/ or angiogenic activity 
characterize the most malignant form termed glioblastoma (GBM, grade IV) [2]. The 
standard of care for treatment of GBM consists of neurosurgical tumour resection and 
concomitant chemotherapy and radiotherapy (RT) followed by adjuvant 
chemotherapy. The most widely implemented treatment regimen has been developed 
by the European Organisation for Research and Treatment of Cancer (EORTC)/ 
National Cancer Institute of Canada (NCIC) Clinical Trials Group, and is often 
referred to as “the Stupp protocol”. In a randomised trial including almost 600 patients 
they clearly demonstrated improved overall survival in patients who received a 
combined modality treatment of temozolomide (TMZ) chemotherapy in conjunction 
with concomitant radiotherapy followed by adjuvant or maintenance TMZ for 6 cycles 
(TMZ/ RT  TMZ), compared to patient who received only RT as initial treatment but 
may have received TMZ chemotherapy at recurrence [3]. 
Nevertheless despite the emergence of novel treatment strategies in recent years 
(discussed in detail below) survival rates for GBM patients continue to be low. 
According to the National Cancer Institute median survival for patients with GBM is 
15 months from time of diagnosis [1], although it may be longer for selected patients 
receiving modern therapy. 
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Development of novel therapeutics having anti-GBM activity remains a critical and 
challenging objective. Moreover, targeting of a single „cancer hallmark‟ [4] is unlikely 
to elicit significant benefit in patients presenting with advanced malignancies. Thus, 
developing molecular targeted drugs that concomitantly impact several GBM survival 
pathways/ „cancer hallmarks‟ is likely to represent a new horizon within the field. 
Nevertheless, notwithstanding the validity of this objective the average cost of 
developing a drug within the healthcare space has over several years increased to 
an average of USD 1.3 billion with sustained investment required over a period of no 
less than ten years. This is none more evident than in the oncology space, where 
molecular targeted therapies (in the context of the evolution of a personalised 
treatment paradigm) comprise a significant sector of the market.  
Reducing the drug development time-line through implementation of molecular 
imaging (MI) strategies during pre-clinical and clinical development phases would 
significantly reduce the burden of cost. MI can improve the efficiency of drug 
screening and may be used to interrogate drug pharmacokinetics and bio-distribution, 
thus markedly reducing time and costs required for the development of a new drug. 
Moreover, identification of MI biomarkers yielding spatial and temporal information 
may also provide surrogate clinical endpoints. Critically, imaging of key biological 
processes which underpin the classical „cancer hallmarks‟ [4] e.g. angiogenesis, 
invasion, proliferation may provide a more robust mechanistic assessment of newly 
emergent molecular targeted therapeutics which represents a cornerstone of 
personalized medicine. This is of note when one considers that chronic treatment 
with targeted therapies results in disease stabilization rather than the tumour 
shrinkage more evident in response to cytotoxic therapies. As such, classical gross 
anatomic imaging of tumour lesions may no longer provide for optimal therapeutic 
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follow up, but rather what is currently required, are imaging modalities that allow for 
sensitive assessment of drug effects at the level of specific targeted molecular 
features/ biological pathways.  
MI optimises streamlines and refines the drug development process. The advantages 
of implementing a MI strategy both during the pre-clinical and clinical development 
stages are illustrated with translational research in primary brain tumours. The 
disease represents particular challenges towards development of novel therapeutics, 
as drugs must be amenable to crossing the blood brain barrier (BBB) 
(notwithstanding BBB breakdown during the disease process) and should efficiently 
compromise the key processes of tumour angiogenesis, invasion and cell 
proliferation. The ability to monitor drug effects on these key biological processes in 
real time will play a key role in elucidating the next generation of molecular targeted 
anti-GBM therapeutics. 
Within the context of the current review, we have, for the first time gathered a multi-
disciplinary team leveraging expertise in cell biology, pre-clinical modelling, 
neurosurgery, MI and neuro-oncology to critically assess the role played by MI in the 
development of a state-of-the-art „next-generation‟ anti-GBM therapeutic paradigm 
which will seek to target multiple cancer hallmarks. 
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Pre-clinical and clinical molecular imaging strategies applied in GBM  
Longitudinal monitoring of tumour progression and drug efficacy are possible thanks 
to real-time non-invasive imaging technologies. These technologies facilitate 
quantitative and qualitative imaging of the primary tumour and record the extent of 
infiltration into the brain parenchyma. State-of-the art MI modalities used to assess 
GBM in both pre-clinical and/ or clinical settings include tomographic imaging, 
nuclear radioisotope-based imaging, optical imaging, and intra-operative 
photodynamic navigation in brain tumour surgeries (See Figure 1 and Table 1). 
 
Magnetic resonance imaging 
A high degree of spatial resolution is facilitated using tomographic approaches. 
Computed tomography (CT) may be initially used in the diagnostic process. However, 
magnetic resonance imaging (MRI) is the gold standard for brain tumour imaging [5]. 
MRI continues to be refined in pre-clinical models and now provides both high-
resolution anatomical information and functional measurements of tumour physiology 
[6]. 
Conventional MRI produces high-resolution brain images that facilitates analysis of 
tumour size, location and extent of associated oedema and lesion necrosis, but does 
provide only little physiological information [5]. Most high-grade tumours, such as 
GBM, lead to a disruption of the BBB with leakage of contrast medium into the 
interstitial space, while low-grade glioma has typically an intact BBB. The increased 
blood flow due to the high density of neo-vasculature, however, does not facilitate 
quantification of contrast uptake as a means of monitoring disease [7]. 
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Advanced MR techniques have now been validated to monitor tumour vasculature 
and study biochemistry of drug responses. MR modalities showing promise in early 
detection of response to treatment and disease progression include proton magnetic 
resonance spectroscopy (1H-MRS), perfusion/ permeability MRI, Diffusion-Weighted 
MRI (DW-MRI) and functional MRI (fMRI). MRS techniques allow for Nuclear MR 
Spectroscopy (NMRS) in a living organism. 1H-MRS is available for clinical MR 
scanners and provides a non-invasive assessment of tumour biochemical features. 
1H-MRS can be performed as part of a standard clinical MRI protocol [8]. 
Furthermore, it has been shown that 1H-MRS using short and intermediate echo time 
(TE) sequences facilitates the differentiation of high-grade cerebral gliomas from 
single metastatic brain tumours [9]. Perfusion MRI may be divided into three 
categories: Dynamic Susceptibility Contrast MRI (DSC-MRI), Dynamic Contrast 
Enhanced MRI (DCE-MRI) and Arterial Spin Labeling (ASL) [5]. DSC perfusion MRI 
allows measurement of cerebral blood volume (CBV), peak height (PH) and 
percentage of signal intensity recovery (PSR) within the brain [10]. DCE-MRI 
assesses tumour perfusion and angiogenesis by monitoring the pharmacokinetic 
uptake and rinsing of an MR contrast agent within the extracellular space of tumour 
lesions. Changes in volume transfer constant (Ktrans) or the initial area under the 
Gadolinium (Gd) concentration time curve in tumour, blood adjusted (IAUCBA) in one 
or more malignant target lesions following drug treatment have been used as primary 
measurements of drug activity [11]. The ASL technique is capable of measuring 
Cerebral Blood Flow (CBF). ASL facilitates cerebral perfusion mapping, without 
administration of a contrast agent or the use of ionizing radiation [12]. An important 
tool in tumour diagnosis is DW-MRI. This technique allows quantification of two 
values: apparent diffusion coefficient (ADC) and fractional anisotropy (FA) (the 
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diffusion of water in one plane). ADC is often correlated with tumour size (an increase 
of ADC values suggests response to therapy, a decrease of ADC values is 
associated with no response to therapy) [13]. Based on the principles of DW-MRI, 
Diffusion Tensor Imaging (DTI) tractography indicates white matter fiber tracts inside 
a tumour and in surrounding tissues [14]. 3D-volumeteric sequences may be fused 
with DTI tractography on an intra-operative navigation computer [5]. Blood Oxygen 
Level Dependent (BOLD) contrast functional MRI (BOLD-fMRI) is well-established 
method for non-invasive localisation of eloquent brain regions in preoperative 
planning for tumour removal. A change in BOLD response (the change in the ratio of 
oxyhemoglobin to deoxyhemoglobin) occurs due to a change in blood flow to the 
active neurological area [15]. The neurosurgeon may integrate anatomic, physiologic 
and metabolic MR images preoperatively in an effort to delineate tumour margins and 
maximise resection (See also Table 1). 
 
Radioisotope imaging 
Compared to MR protocols, radioisotope imaging is less well established for GBM 
patients in the clinical setting. However, benefits from radioisotope imaging may be 
obtained at primary diagnosis, for planning of biopsy/ surgery targeting at the highest 
grade area, and in post-treatment radiological follow-up. Positron emission 
tomography (PET) based on the detection of pairs of gamma rays, which are 
produced when a positron emitted by a PET tracer encounters an electron. 
Computed image reconstruction is used to generate a three dimensional (3-D) image 
of tracer concentration at a given location [16]. 
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The most common PET radiotracer used to visualise primary tumours and tumour 
metastases is the glucose analogue 18F-Fluorine-2-Deoxy-D-Glucose (FDG). 
Tumour cells exhibit high level of glucose metabolism and up-regulation of glucose 
transporters (GLUTs) when compared to non-tumour cells. However, due to high-
glucose metabolism in normal brain tissue resulting in a significant physiological FDG 
uptake, 18F-FDG-PET application for detecting glioma or for interrogating anti-glioma 
therapeutics is limited [17]. 
As such, several alternative radiotracers having a lower background uptake in the 
brain have been developed to date, such as amino acid tracers (11C-methionine 
(MET), 18F- O-(2-18F-fluoroethyl)-L-tyrosine (FET) and α-11C-methyl-L-tryptophan 
(AMT)), the thymidine analog (18F- fluorothymidine (FLT)), 11C-choline (CHO), 18F-
fluoromisonidazole (FMISO), 18F-Fluciclatide and 18F-Galacto-Arginine-glycine-
aspartate (RGD). The most widely used alternatives for 18F-FDG are the radio-
labelled amino acid tracers. It has been reported that amino acid PET tracers may 
have utility in microsurgical and radiotherapy [18]. The 11C-MET radiotracer 
visualises elevated amino acid transport in endothelial and tumour cells being 
valuable for detection of tumour size and glioma cell invasion [19]. The amino acid 
18F-FET further represents a promising radiotracer for targeting biopsy sites, 
delineating tumour extent, diagnosing recurrence and determining tumour volume 
[20]. Further, 11C-AMT was shown to identify tumour-infiltrated brain tissue not 
detectable by conventional MRI in newly diagnosed GBMs. Moreover, elevated 11C-
AMT uptake was not observed in areas of vasogenic oedema [18]. The thymidine 
analog, 18F- FLT has been developed as a PET tracer to image tumour cell 
proliferation in vivo. Uptake of 18F-FLT by proliferating tissues occurs through 
activation of thymidine kinase [21]. Evaluation of brain tumour malignancy and glioma 
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differentiation may also be assessed using 11C-CHO PET tracer. CHO is a natural 
blood constituent, which penetrates cell membranes. The uptake rate of 11C-CHO 
within tumour tissue has shown to be proportional to the rate of tumour cell 
duplication [17]. 18F- FMISO represents yet another PET radiotracer of interest with 
regards to brain tumours. FMISO is a pro-drug which becomes activated in hypoxic 
tissue and is subsequently inhibited in the presence of oxygen. [22]. PET 
radiotracers, such as 18F-Fluciclatide and 18F-RGD, have also been evaluated in 
GBMs. Fluciclatide binds with high affinity to αvβ3 and αvβ5 integrins, whereas the 
tripeptide sequence, RGD, binds to αvβ3 only [23]. 
Single photon emission computed tomography (SPECT) represents a further imaging 
modality based on selective radioisotope uptake. A gamma camera is rotated around 
a subject to obtain multiple two dimensional (2-D) images of SPECT tracer 
distribution. A 3-D image is generated by computer processed tomographic 
reconstruction of the 2-D image dataset. SPECT tracers directly emit gamma 
radiation [24]. 
With respect to SPECT, Thallium-201 (201Tl), Technetium-99-m 
methoxyisobutylisonitrile (99mTc-MIBI) and 3-123I-iodo-α-methyl-L-tyrosine (123IMT) 
radiotracers have been implemented in evaluation of brain tumour progression. 201Tl 
is preferentially taken up by neoplastic glial cells. Use of this tracer is limited as 201Tl 
SPECT exhibits low sensitivity in the detection of low-grade lesions with an intact 
BBB [25]. More sensitive SPECT tracers, known are 99mTc-MIBI and 123IMT. 
99mTc-MIBI is stored in mitochondria and cytoplasm of metabolically active cancer 
cells due to an active transport mechanism and has been shown to have utility in the 
determination of histological grade and to determine GBM follow up [26], whereas the 
amino acid derivate 123IMT has been evaluated to determine metabolic activity of 
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brain tumours and further to distinguish tumour recurrence from radiation necrosis 
and peri-tumoural oedema. Moreover, as the uptake of 123IMT is less dependent on 
BBB damage, it may be more suitable in the detection of low grade tumours than 
201Tl SPECT [27] (See also Table 1). 
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Optical imaging  
An essential pre-clinical tool for monitoring disease progression and therapeutic 
response at the molecular level is non- (or minimally) invasive optical imaging. 
Bioluminescence imaging (BLI) is based on the production of light following a 
multistep, enzymatic reaction of luciferase with its substrate (luciferin or 
coelenterazine), which can be visualised with an external detector. Firefly luciferase, 
in the presence of adenosine triphosphate (ATP) and molecular oxygen, catalyzes 
the oxygenation of luciferin to form a highly unstable, electronically excited oxy-
luciferin. Photons of light are released upon relaxation of oxy-luciferin to its ground 
state [28]. BLI has been implemented in GBM tumour model systems and is 
established as a reliable tool in the assessment of tumour progression over time and 
in the pre-clinical evaluation of drug efficacy. The main advantages of BLI include the 
ability to non-invasively monitor tumour progression and treatment efficacy, ease of 
use, relatively inexpensive equipment, and the possibility to image more than one 
animal at the same time. The major disadvantage of BLI is that genetic expression of 
luciferase is a fundamental requirement. Therefore, its application is limited to the 
pre-clinical setting [29]. 
Fluorescence imaging (FLI) is based on the excitation of a fluorescent molecule with 
visible light, resulting in emitted light, which can be utilised for imaging purposes. 
Although extensively used in vitro, utilisation of FLI in vivo is limited by tissue light 
penetration [30]. Nevertheless, over the past several years significant advances have 
been made to implement this technology in vivo using wavelength tissue penetrating 
light.  
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In particular, near-infrared fluorescence (NIRF) imaging has been successfully 
applied as a powerful tool for imaging GBM at the molecular level in pre-clinical small 
animal models. NIRF imaging uses wavelengths in the 700- to 900-nm range where 
light absorbance and scattering are significantly lower and auto-fluorescence of 
normal tissues is minimally detected. As an example, the NIRF dye Cy5.5 associated 
with a targeted probe has proven to be a promising contrast agent for in vivo tumour 
visualisation. In vivo NIRF imaging of the integrin αvβ3 using an RGD-Cy5.5 conjugate 
has been further shown to represent a highly sensitive technique for tumour detection 
in GBM xenograft models [31]. 
Translation of optical imaging in the clinical GBM setting is limited to intra-operative 
applications. Implementation of intra-operative photodynamic navigation based on 
optically active imaging agents has been shown to provide benefits during GBM 
surgeries. 5-aminolevulinic (5-ALA) is a non-fluorescent naturally occurring precursor 
of haemoglobin, which can be administered orally and which is metabolized by 
tumour cells of epithelial and mesenchymal origin leading to intracellular 
accumulation of the fluorescent dye Protoporphyrin IX (PpIX). Once exposed to violet 
blue light, cells with high concentrations of PpIX illuminate with red light. When the 
extent of resection guided by 5-ALA fluorescence was compared to that achieved by 
resection under normal white light, higher rates of complete resection were observed 
in a group of patients assigned to the 5-ALA group [32]. Thus, fluorescent-guided 
resection provides the neurosurgeon with real time visual recognition of tumour 
material (See also Table 1). 
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Multimodality imaging strategies 
Multimodal imaging approaches, which have reached the clinical setting, combine 
PET and/ or SPECT with CT or MRI [18,19,33]. As discussed, PET enables non-
invasive visualisation of tumour metabolism, neuronal function, and therapeutic gene 
expression (see Figure 1 for advantages and disadvantages of PET). CT or MRI 
completes this information with anatomical data (see Figure 1 for advantages and 
disadvantages). The utility of applying such a multi-modality approach in monitoring 
cancer progression or therapeutic efficacy is well established and will be discussed 
further in the next section [34]. 
The development pipeline for novel anti-GBM therapeutics often combines methods 
of imaging to deliver more detailed information on tumour growth and metabolism 
and to mechanistically interrogate response to treatment at the molecular level in a 
spatially sensitive (e.g. anatomic) setting. In pre-clinical studies it is now possible to 
implement BLI protocols in parallel with conventional MRI (see Figure 1 for 
advantages and disadvantages). This multimodal imaging approach provides 
valuable information with respect to early identification of tumours (BLI), tumour 
localisation (MRI), volumetric measurements (MRI), efficient measurement of 
response to therapeutics (MRI and BLI) and further facilitates high-throughput 
analyses (BLI). Generally, BLI signal has been found to correlate well with MR 
measurements of tumour volume [35]. However, some limitations relating to the use 
of BLI alone in the context of translational GBM research have been noted. As shown 
by Jost et al., at early time points following tumour implantation, false 
bioluminescence signal can be generated by the presence of intra-parenchymal 
haemorrhages and extensive hydrocephalus at the site of injection. Lack of 
correlation with MRI-determined tumour volumes has also been shown at late stages 
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of tumour growth, when bioluminescence signal is lost due to the presence of 
hemorrhagic and necrotic tissue, whereas tumour volumes continue to increase 
which is evident on MRI [36]. Therefore a BLI/ MRI multimodal strategy is of 
significant benefit within the pre-clinical setting. 
PET and optical imaging have been recently combined. Radioactive materials are 
able to produce low energy visible photons (1.2 to 3.1 eV, 400 to 1000 nm) 
associated with Cerencov or Bremsstrahlung radiation. Thus, radioactive molecular 
probes may be non-invasively imaged using commercially available optical imaging 
instruments. The main advantages of imaging radioactive probes using optical 
imaging include lower capital costs, high-throughput imaging and wider accessibility 
of optical imaging instruments when compared with PET and SPECT scanners [37]. 
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Application of MI strategies in the pre-clinical development and clinical 
evaluation of a novel GBM therapeutic paradigm 
The increasing use of MI in translational GBM research as well as evolution of the 
GBM imaging field has facilitated pre-clinical and clinical interrogation of both gold-
standard and „next generation‟ therapeutics. The expanding complexity of the MI 
space, to include novel MR techniques and PET based approaches, support the 
emergence of a novel GBM treatment paradigm based on the targeting of multiple 
cancer hallmarks and is likely to result in the identification of new imaging as well as 
therapeutic targets. Examples of how MI contributes to the evolving GBM therapeutic 
paradigm are discussed below (See also Table 2). 
 
Angiogenesis inhibitors  
As with all neoplastic lesions, growth and survival of GBM is dependent on a blood 
supply. Complex interaction of angiogenic factors, such as vascular endothelial 
growth factor (VEGF), results in the formation of new blood vessels. Thus, 
angiogenic factors and pathways participating in the angiogenesis process are 
targets for GBM treatment.  
Currently the sole angiogenesis inhibitor licensed by the Food and Drug 
Administration (FDA) for use in GBM is bevacizumab following two successful phase 
II trials, although its value in brain tumours remains a matter of debate [38,39]. 
Cediranib (AZD2171, Recentin™, a small molecule, orally bioavailable tyrosine 
kinase inhibitor (TKI) of VEGFR2, PDGF, receptor-α and –β, and stem growth factor 
–receptor (c-Kit) [40]) and cilingitide (EMD121974, a cyclic RGD-mimetic peptide 
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selective inhibitor of both αvβ3 and αvβ5 integrins) has been investigated in the 
treatment of recurrent GBM, but have failed to prolong survival in a phase III 
randomised trial. Other more conventional, multi-targeted tyrosine kinase inhibitors 
(TKIs), such as sunitinib and sorafenib, (which inhibit activation of downstream VEGF 
receptor (VEGFR-2), signalling pathways as well as targeting other pathways 
involved in angiogenesis including PDGFR, fms-related tyrosine kinase 3 (FLT3), c-
KIT [41] etc) showed pre-clinical promise for application in the GBM setting [42]. 
However, to date there is lack of available clinical data demonstrating significant 
benefit of sunitinib and sorafenib in GBMs [43,44]. Resistance to angiogenesis 
inhibition is likely a complex and multi-factorial event which may at least partially be 
explained by activation of compensatory „cancer hallmark‟ pathways [4]. 
Angiogenesis inhibitors nevertheless still represent a potentially promising approach 
in targeted GBM therapy though it is likely that the future of this class of agents will 
be based on application within combination treatment regimens. Defining AI 
treatment response using imaging is challenging as AIs may be cytostatic rather than 
cytotoxic. Obvious reductions in tumour size (according to Response Evaluation 
Criteria in Solid Tumours (RECIST) criteria) as measured by conventional imaging 
techniques may not be evident despite an apparent clinical benefit. Thus, it has 
proven difficult to obtain accurate response rates when using standard T1- and T2-
weighted MR images to analyse benefits of angiogenesis therapy in GBM patients 
[45]. Despite limited availability, novel GBM imaging methods have proven effective 
in measuring treatment response. These methods include DSC-MRI, DCE-MRI, DW-
MRI and PET as discussed above.  
DSC-MRI can further provide information on vascular re-modelling and may be used 
as an early indicator of response to AI therapy as shown in patients treated with 
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enzastaurin in combination with TMZ [46]. Sorenson et al. have used DCE-MRI to 
measure Ktrans in patients treated with the TKI cediranib. By combining Ktrans values 
with biomarkers (micro vessel volume and circulating collagen IV) the authors 
calculated a „vascular normalization index‟ which was predictive of overall survival 
(OS) and progression-free survival (PFS) following a single dose of cediranib [47]. 
DW-MRI can provide information on tumour cellularity and response to treatment by 
estimating ADC [48,49]. DW-MRI has been used to examine ADC voxel changes in 
the same patient over time, creating functional diffusion maps (fDMs). In GBM 
patients treated with bevacizumab, nonlinear registration of pre-treatment ADC maps 
to post-treatment ADC maps demonstrated improvement in clinical predictability, 
sensitivity and specificity of fDMs for both PFS and OS [50]. Moreover, Gerstner et al. 
have further elucidated the benefits of ADC maps in assessing cell infiltration after 
treatment with anti-VEGF agent, cediranib. Regions of tumour growth that are not 
visible on contrast-enhanced MRI may be visualized using DW-MRI technique [13]. 
PET further represents an evolving technique for assessing GBM therapeutic 
response to anti-angiogenic therapies [51]. In comparison to anatomic imaging, 
tumour metabolic response to anti-angiogenic treatment has been suggested as a 
more powerful method for predicting OS. A pilot clinical study demonstrated a 
correlation between reduced FLT uptake and improved OS in GBM patients treated 
with a combination of irinotecan and bevacizumab. Thus, FLT-PET has been 
suggested as an imaging biomarker for predicting survival benefit in response to anti-
VEGF therapy in patients with recurrent GBMs [52]. Moreover, a pre-clinical study 
using the novel tracer 18F-Fluciclatide in a U87MG-based xenograft model provided 
evidence of a method to measure tumour response to anti-angiogenic therapy with 
sunitinib. This study demonstrated that assessment of the response to anti-
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angiogenic therapy using 18F-Fluciclatide-PET to measure αVβ3 and αVβ5 integrin 
expression on GBM cells and the vasculature was observed before any significant 
changes in tumour size were evident using the current standard tumour calliper 
measurements. Moreover, 18F-Fluciclatide tumour uptake was useful in assessment 
of tumour necrosis and integrity [23]. 
Thus, the multitude of tracers currently under investigation suggests that PET may 
play an important role in for early evaluation of the efficacy of AIs and other targeted 
agents [53]. Moreover, with the emergence of AIs in the treatment of GBM it is 
imperative that the most appropriate imaging modalities are used to determine 
tumour response to treatment. Importantly, in light of the resistance to AI therapy 
evident in the clinic [54] and given the most recent data which has emerged to 
suggest a paradoxical up-regulation of invasive pathways in response to AI 
treatment, a future therapeutic strategy may include targeted therapies to 
compromise both angiogenic and invasive pathways [55]. Thus, the ability to 
sensitively monitor GBM tumour cell invasion in vivo is likely to become increasingly 
important. 
  
EGFR inhibitors 
The Epithelial Growth Factor Receptor (EGFR) family comprises an important group 
of receptor tyrosine kinase (RTK) molecules. These molecules include the closely 
related trans-membrane proteins: ErbB-1 (EGFR, HER1), ErbB-2 (neu, HER2), ErbB-
3 (HER3) and ErbB-4 (HER4). Major downstream signalling pathways activated by 
EGFR include Ras/Rapidly Accelerated Fibrosarcoma (Raf)/MAPK Kinase 
(MEK)/Extracellular signal Related Kinase (ERK) 1/2/MAPK and PI3K/AKT. 
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Physiologically, EGFR is activated by epithelial growth factor (EGF) and related 
ligands thus mediating cellular growth and differentiation in both embryo and adult 
[56]. Deregulation of this pathway occurs in approximately 40 % of patients with GBM 
and results in increased proliferation, invasion, angiogenesis and tumour survival. 
Recently EGFR expression has been associated with resistance to standard chemo- 
and radiotherapy.  
Strategies exist to target EGFR, most notably monoclonal antibodies (mAbs) 
targeting the extracellular epitope (e.g. cetuximab) or small molecule receptor 
tyrosine kinase inhibitors that target the intracellular kinase domain (getifinib and 
erlotinb). Gefitinib and erlotinib are small molecule TKIs, which have undergone 
numerous phase I/II trials either in single agents or combination protocols. Both are 
orally bio-available, well tolerated and have demonstrated significant anti-GBM 
activity in pre-clinical trials. However, these findings did not translate consistently in 
clinical trials [57,58].  
Using MI, Mukherjee et al. investigated the molecular mechanism by which the 
EGFRvIII mutation confers resistance to radiotherapy in vivo. An orthotopic 
intracranial luciferase expressing U87-EGFRvIII mouse model was implemented to 
assess tumour growth dynamics following whole brain radiotherapy. The authors 
provided evidence that EGFRvIII expression activates a DNA double-strand break 
repair enzyme by up-regulation of the PI3K-AKT-1 pathway. Activation of this enzyme 
reverses the DNA damage induced by ionizing radiation. The authors were able to 
demonstrate that combining EGFR inhibition with a PI3K inhibitor attenuated the rate 
of DSB repair providing a rationale for combining these drugs [59].  
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A chimeric antibody (Ch806) binds to the EGFR deletion variant de2-7 EGFR 
(EGFRvIII) and has shown efficacy in pre-clinical GBM models [60]. Ch806 labelled 
with a positron emitter characterised by a relatively long half-life, such as 124I or 
89Zr facilitates non-invasive quantification of de2-7 EGFR expression in vivo via 
immuno-PET, which represents an attractive and novel approach to improve tumour 
characterisation. As mAbs target specific tumour markers or predominant antigens, 
immuno-PET provides not only higher-resolution images but also facilitates tumour 
targeting and mAb quantification in targeted and non-targeted tissues. 
Implementation of immuno-PET in experimental studies for newly developed 
antibody-based anti-GBM therapies may facilitate the selection of patients which can 
benefit from expensive mAb-based therapy [61,62]. Immuno-PET may be developed 
to non-invasively characterise the growth factor receptor status (EGFR, PDGFR and 
VEGFR) of patients with GBM before surgery, which would allow us to predict 
response and tailor therapy accordingly. Along a similar line, but combining MI with a 
therapeutic strategy, Hadjipanayis et al. orthotopically inoculated U87ΔEGFRvIII 
GBM cells into nude mice. EGFRvIII antibody was conjugated to iron oxide 
nanoparticles and on day 7 post-inoculation particles were delivered by intracerebral 
convection enhanced delivery. The authors were able to demonstrate not only a 
survival benefit but also specific uptake of the nanoparticles by GBM cells as noted 
by a signal drop on T2-weighted images. This approach combines treatment with a 
sensitive imaging modality as the conjugated iron oxide particles act as a specific 
MRI contrast agent for glioma cells [63].  
Despite immune-PET, which showed to be promising in non-invasive quantification of 
receptor expression, an association between MR perfusion and the identification of 
EGFRvIII-positive GBMs has been demonstrated in large group of human GBMs and 
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showed to have clinical significance in personalised treatment (e.g. patient selection, 
investigation of therapeutic sensitivity). It has been reported that the EGFRvIII-
expressing GBM patients would demonstrate increased relative tumour blood volume 
(rTBV). One of the factor which contribute to the increased rTBV is EGFRvIII-
mediated upregulation of VEGF and enhancement of angiogenesis. Moreover the 
association between rTBV and EGFRvIII was demonstrated regardless system that 
has been used and showed weaker correlation between rTBV and VEGF. This 
imaging-based analysis may be of particular use in postoperative diagnosis of 
EGFRvIII expression in residual tumour and EGFRvIII-directed therapy choice. The 
use of MR perfusion as a noninvasive imaging of GBM EGFRvIII status encourages 
for further exploration (figure 2).  
Measuring the downstream effects of EGFR inhibitors on tumour burden may be 
successfully achieved using optical methods in the pre-clinical setting or by MR 
protocols in both pre-clinical and clinical settings. Using these MI strategies as 
described it is becoming clear as to why EGFR inhibitors when delivered as a 
monotherapy have not translated well in the clinical setting and helps establish a 
rationale for using combinations treatment approaches. Importantly MI has further 
helped establish a mechanism for the role played by EGFR amplification in the 
observed resistance to standard therapy. These findings highlight the prognostic 
significance of quantifying EGFR status in the tumour. Non-invasive quantification of 
receptor expression using an antibody tagged with a PET tracer and/or MR perfusion 
may be of translational relevance. 
 
mTOR inhibitors  
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mTOR is a serine/ threonine kinase which belongs to the PI3K-related family. It is a 
central integrator of intracellular and extracellular signals involving growth, 
proliferation, nutrient and energy status [64]. mTOR acts both as an upstream 
regulator and downstream effector of PI3K [65] and is found in two distinct protein 
complexes (mTORC1 and mTORC2). The PI3K/ mTOR signalling pathway is 
deregulated in approximately 50 % of patients with GBMs. First generation inhibitors, 
which are analogues of rapamycin, are termed rapalogs and inhibit mTORC1. The 
two main categories of second generation mTOR inhibitors are mTOR/ PI3K dual 
inhibitors and mTORC1/ mTORC2 dual inhibitors, which are at various stages of 
phase I and phase II clinical development for solid and haematological malignancies 
[66]. 
Cellular metabolism and energy status is mediated by the mTORC1 complex. 
Glucose uptake and therefore intracellular AMP/ ATP ratio modulate mTORC1 
activity via an AMPK dependent pathway, whereas growth and proliferation are 
mediated by both mTORC1 and mTORC2. Using small animal PET, Wei et al. have 
utilized a subcutaneous GBM mouse model to investigate the effect of rapamycin on 
tumour metabolism and growth. Over a 72 hour period rapamycin decreased 18F-
FDG and 18F-FLT uptake. Thus, it has been proposed that 18F-FDG may be used to 
monitor tumour response in clinical trials involving mTOR inhibitors [67]. Within the 
context of the „Warburg effect‟, GBM cells convert most glucose to lactate at the 
expense of ATP production. This occurs independently of O2 availability by the 
enzyme hexokinase 2. The resulting glucose metabolites are utilized for anabolic 
processes. As well as sensing AMP/ ATP ratios via AMPK, the PI3K/ mTOR pathway 
also regulates other aspects of glycolysis such as glucose transporters and glycolytic 
enzymes. To interrogate this feature of GBM tumour cell metabolism, Chaumeil et al. 
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studied the effect of everolimus, a rapamycin analogue, on the GBM cell line GS-2 in 
an orthotopic rat model. Through implementation of hyperpolarized 13C-MRS 
imaging, the authors noticed a significant reduction in lactate-to-pyruvate production 
by day 7 of treatment where conventional MRI was only able to detect a change in 
tumour volume at day 14. Thus, the use of hyperpolarized 13C-MRS imaging in 
clinical MR application was recommended to monitor early response to molecularly 
targeted treatments (figure 3) [68]. These findings were in line with other reports 
proposing the use of hyperpolarized 13C-MRS imaging to detect tumour and 
response to treatment [69]. Over-expression of platelet derived growth factor receptor 
(PDGFR), a common genetic mutation in GBM, leads to deregulation of the PI3K/ 
Akt/ mTOR pathway. Pitter et al. investigated the combination of CCI-779 (a lipid 
soluble analogue of rapamycin) with perifosine (an alkylphospholipid that interferes 
with Akt recruitment) in genetically engineered PTEN-intact and PTEN-deficient 
PDGF-driven mouse models of GBM. Activated Akt modulates mTOR activity. Using 
standard MR sequences, T1 with gadolinium and diffusion weighted sequence 
analysis, the authors observed reduced tumour enhancement and a corresponding 
decline in ADC values. Their findings supported the rationale for testing this novel 
therapeutic combination in the human PDGF-subgroup of GBM and highlighted the 
importance of inhibiting Akt and mTOR simultaneously [70].  
As single-agent mTOR inhibitors continue to show no significant benefit, design of 
novel molecular targeting combinations is warranted. At present, mTOR inhibitors are 
undergoing assessment in clinical trials in combination with TMZ with or without 
radiation in patients with GBM. Undoubtedly, use of metabolic MI strategies (such as 
hyperpolarized 13C magnetic resonance spectroscopic imaging and PET) in the 
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interrogation of mTOR pathway inhibition has highlighted its central role in GBM 
metabolism.  
 
Gene therapy  
Use of nucleic acids to deliver therapeutic genes to GBM cells provides an alternative 
anti-GBM therapeutic approach [71]. To date, the use of recombinant adenoviruses 
[72] and herpes simplex virus type 1 (HSV-1) vectors [73,74] has shown some 
promise, although they failed to improve outcome in randomised clinical trials. Gene 
delivery vectors locally transduce brain tumour cells with therapeutic genes, which 
may then influence biological properties of cancer cells by inhibiting angiogenesis 
[75], stimulating the immune response [76] or triggering apoptosis thus targeting 
several „cancer hallmark‟ pathways [77]. Nevertheless, efficacy of gene therapy in 
GBM patients may be compromised due to tumour tissue heterogeneity causing 
restricted transduction efficiency. Several strategies for non-invasive and quantitative 
imaging of gene expression in vivo have been developed over the past years. 
Implementation of MI in gene therapy protocols provide better clinical outcome of 
novel gene therapy approaches through non-invasive assessment of the dynamics of 
gene regulation, signal transduction and monitoring the induction and regulation of 
therapeutic genes [71]. 
Our co-author (A.H. Jacobs), has successfully employed PET to non-invasively 
identify viable target tissue. Radiotracers implemented (18F-FDG, 11C-MET and 
18F-FLT) were well correlated with histological signs of viable and necrotic tissues. 
Multimodal, image-guided vector application was used to deliver vector particles into 
viable tumour tissue. Tumour localization was based on MRI whereas viable target 
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tissue was successfully identified using 18F-FDG-PET. PET was also used to co-
register and determine total tissue dose of vector-mediated gene expression (18F-
FHBG), and to assess tumour proliferation prior to and following therapy (18F-FLT) 
[78]. Another radiotracer 18F-Fluoro-3-[hydroxymethyl]-butyl)-guanine (FHBG) 
employed in this study sensitively and specifically detects PET reporter genes. 18F-
FHBG normally cannot cross the BBB, however it may accumulate within GBM 
tumours where the BBB is compromised [79]. The study revealed that multi-tracer 
PET scanning is of use in the development of safe and efficient gene therapy 
protocols. Multimodal imaging approaches have also been successfully employed by 
Winkeler et al. in experimental GBMs. Tumours were localized using MRI and PET 
(18F-FDG/ -FLT) protocols were implemented to assess viable target tissue for 
vector application. Doxycycline-dependent gene expression over time was further 
assessed by 18F-FHBG-PET and BLI [80]. In the clinical setting, gene therapy 
efficacy may be assessed using MRI. As an example, a group of patients with 
recurrent GBM treated with the combined suicide (thymidine kinase of HSV-1, HSV-
TK) and immuno-modulating (human interleukin-2, IL-2), suicide/ cytokine gene 
therapy was monitored using MRI. Using serial MRI scans monitoring tumour 
regression, presence of necrosis and/ or inflammation around the injection site of the 
vector and tumour recurrence was assessed [81]. Nevertheless, in order to provide 
more detailed information (e.g. to identify targeted tissue and/ or assess vector-
distribution volume) multi-modality imaging ideally should be implemented in clinical 
protocols. Voges et al. employed MRI and PET to monitor response of patients with 
recurrent GBM to stereotactically guided intra-tumoural convection-enhanced delivery 
of HSV-TK gene–bearing liposomal vector and systemic ganciclovir. MI was shown to 
be essential for visualizing therapeutic effects on tumour anatomy, metabolism and 
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gene expression. Focal therapeutic effects on tumour metabolism, as assessed by 
11C-MET-PET, revealed reduced MET activity. However, results obtained from T1-
weighted MRI scans indicated increased tissue volume based on Gd uptake 
indicating increased therapy-induced BBB permeability. The complementary 
information provided by PET and MRI indicates that multi-modal imaging for the 
identification of target tissue and response to gene therapy represents to an essential 
technology in this evolving field (Figure 4) [82].  
As highlighted above, implementing MI (mainly novel PET approaches) into gene 
therapy protocols at both pre-clinical and clinical stages is of significant utility in 
identifying target tissue and enabling application of targeted vectors. 
 
Therapeutic stem cell approaches 
It is now widely believed that GBM tumours recur due to the presence of a 
subpopulation of cancer cells having stem cell-like properties (CSC) [83]. The CSC 
hypothesis assumes that CSCs remain unresponsive due to high resistance to radio- 
and/ or chemotherapy. CSCs are thought to be responsible for tumour re-growth post 
multimodal therapy [84]. The CSC hypothesis suggests that tumour bulk therapy 
(targeting only differentiated tumour cells) may fail due to GBM heterogeneity and 
invasive phenotype, thus allowing tumour progression and relapse. As such, 
molecular targeting of GBM CSCs subpopulations may lead to long-term treatment 
response and halt tumour progression [85]. As GBM CSCs represent only a small 
subpopulation of the entire tumour, their detection in vivo is likely to be challenging. 
Therefore, experimental protocols which interrogate the potential efficacy of GBM 
28 
 
CSC targeted therapeutics should ideally comprise highly sensitive MI approaches 
[86]. 
GBM CSCs may be targeted through inhibition of the nitic oxide (NO) pathway. The 
critical enzyme in this pathway is nitric oxide synthetase-2 (NOS2), which catalyzes 
the production of NO from L-arginine. NOS2 is expressed in glioma cells exhibiting 
high levels in GBM CSCs stimulating tumour growth and reducing tumour response 
to chemotherapy. The anti-GBM efficacy of BYK191023, a lipophilic NOS2-selective 
inhibitor has been effectively tracked using BLI in two different patient-derived, 
luciferase-expressing GBM xenografts. Although BYK191023 did not reduce tumour 
growth completely, significant tumour growth delay was successfully demonstrated 
by non-invasive imaging (Figure 5) [87]. Another potential therapeutic target may be 
inhibition of the NOTCH signalling pathway. NOTCH signalling activates several 
genes essential for maintenance and renewal of neural stem cells. Increased NOTCH 
activity has been linked with tumour growth promotion, whereas blockade of the 
NOTCH pathway inhibits proliferation and or/survival. In vivo studies have shown that 
blockade of NOTCH signalling pathway through inhibition of γ-secretases can restrict 
GBM CSCs activity in vitro and tumour formation in vivo. Blockade of the NOTCH 
signalling pathway has been targeted using the γ-secretase inhibitor (GSI-18) and 
tumour response monitored using MRI. Multiple T2-weighted scan slices confirmed 
that GSI-18 treatment blocked formation of tumours and prolonged survival [88]. In 
the past decade, interest has focused not only on identifying therapies, which target 
GBM CSCs, but also towards utilizing stem cells as a potential tool for cell-based 
treatment of GBM. The use of stem cells as vehicles for therapeutic agents is based 
on their ability to migrate to brain tumours irrespective of the BBB. Thus far, three 
types of stem cells have been tested as vehicles for various therapeutic agents: 
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embryonic, neural and mesenchymal. Several MI strategies have been implemented 
to examine and track stem cells used as delivery vehicles for anti-GBM therapeutics 
[89]. As proposed by Chien et al.  a cellular MR technique can be successfully used 
to track mesenchymal stem cells in vivo once the cells are labelled with suitable MRI-
visible particles prior to transplantation, such as superparamagnetic iron oxide (SPIO) 
nanoparticles. SPIO nanoparticles used with clinical 1.5-T MRI system revealed that 
mesenchymal stem cells used as delivery vehicles for therapeutic agents are able to 
migrate toward GBM in vivo being a promising strategy in anti-GBM treatment [90]. In 
order to visualise stem cell-based therapeutic interventions in a mouse model of 
GBM, optical imaging has also been used [91,92]. As demonstrated by Doucette et 
al., BLI successfully tracked mesenchymal stem cells and detected them in the right 
frontal lobe where tumour was identified. Moreover, through optical imaging the 
viability of mesenchymal stem cells may be confirmed [91]. Efficacy of therapeutic 
stem cells encapsulated in biodegradable, synthetic extracellular matrix (sECM) has 
been non-invasively monitored using BLI employing a clinically relevant GBM mouse 
model following tumour resection. BLI was efficiently used to follow both un-resected 
and resected intracranial tumours and to track stem cells in vivo. Serial monitoring 
revealed that stem cells encapsulated in sECM survived longer in the GBM resection 
cavity as compared to non-sECM-encapsulated cells. Furthermore, bioluminescence 
measurements revealed that TRAIL-secreting sECM-encapsulated stem cells 
transplanted in the resection cavity significantly delayed tumour re-growth in well 
established U87 and primary invasive GBM8 mice bearing GBM models. Stem cells 
encapsulated in sECM effectively extended the drug exposure time to tumour cells 
resulting in prolonged survival of mice treated with S-TRAIL [92].  
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Therefore, as indicated, optical imaging has provided evidence that stem cell-
mediated GBM therapy offers a continuous, selective and concentrated local delivery 
of S-TRAIL, showing higher treatment efficiency. Sensitive MI approaches, which 
provide high resolution images, are important in stem cell research most critically due 
to stem cell infiltrative phenotype and low number of CSCs present. 
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Conclusions and future directions  
MI is increasingly emerging as a critical tool existing at the interface between pre-
clinical and clinical translational research towards identification of a next-generation 
GBM therapeutic paradigm.  
Availability of reliable pre-clinical animal models, which recapitulate human 
pathology, when combined with suitable, state-of-the art translational, imaging 
modalities, has to-date facilitated significant advances in the field. Implementation of 
imaging protocols during pre-clinical development of novel anti-GBM therapeutics is 
now well recognized as a key strategy for non-invasive and longitudinal assessment 
of therapeutic effects, reduction of drug development costs, time and animal 
requirements. Pre-clinical assessment of therapeutic response with molecular 
imaging also may offer greater potential to facilitate translational development 
research of novel anti-GBM therapies. 
The ubiquity of MI approaches in clinical practice coupled with its versatility (providing 
information on anatomic, physiologic and metabolic processes) underscores the large 
utility of this modality. Combination of anatomical (MRI or CT) with metabolic (PET or 
SPECT) imaging techniques may provide even more detailed information on 
response to drug treatment compared to single PET/ SPECT or MRI/ CT imaging 
alone. Implementation of and early imaging biomarker studies may be useful in 
predicting failure of therapy, planning the development of a drug and allow 
personalised cancer therapy [93]. 
As described above, the challenges exist in interpretation of conventional MRI as the 
primary imaging modality for initial diagnosis and assessment of treatment response 
32 
 
in patients with GBM. Therefore, new types of imaging are currently investigated 
aiming to improve accuracy of tumour assessment following treatment. 
The standard, 2-dimensional measurement of contrast enhancement (the Macdonald 
Criteria) [94] to evaluate treatment response in GBMs has been used in neuro-
oncology for many years. However, these criteria do not reflect functional, 
morphologic, or metabolic changes that may occur with conventional chemotherapy 
or targeted chemotherapy. The use of MI modalities may improve the study of 
complexity and heterogeneity of GBMs not only at the time of initial diagnosis but 
also during the treatment. Therefore, a rational selection of the imaging modality is 
important for the assessment of tumour response to treatment and should take into 
account the mechanism of action of the drug. 
New criteria for tumour response assessment (the Response Assessment in Neuro-
Oncology (RANO) Criteria), that have recently been published incorporate non-
enhancing tumour progression in evaluation of treatment response in GBMs [95]. 
Nevertheless, detection of non-enhancing tumour and pseudoprogression are still the 
two major challenges in neuro-oncologic imaging. 
Non-invasive MI may improve personalised medicine by providing detailed molecular 
information relating to drug mechanism of action. Current efforts to define a new 
treatment paradigm for GBM are primarily focused on targeted therapies. 
Nevertheless, it is becoming increasingly apparent that targeting a single „cancer 
hallmark‟ in GBM may be insufficient to affect a sustained response. Thus, a 
combined „anti-cancer hallmark‟ approach is warranted, for example concomitantly 
targeting angiogenesis and invasion pathways or angiogenesis and metabolic 
pathways. Moreover, the contribution of GBM CSCs to drug resistance and thus 
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evolution of GBM CSC targeted therapies will no doubt contribute to the emerging 
next generation GBM therapeutic paradigm. Evolution of increasingly sensitive MI 
approaches, in particular to provide information on extent of tumour and CSC 
invasion into normal tissue, will likely play a key role in this effort. In short, 
considering GBM heterogeneity and the importance of personalized therapy within 
the context of patient care, state-of-the-art MI approaches which inherently facilitate 
GBM targeted therapeutic follow up should ideally be implemented in clinical 
development.  
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Figure legends 
 
Figure 1 Imaging modalities employed in the pre-clinical and clinical 
development of novel GBM treatment strategies  
46 
 
Images used show examples of: photodynamic navigation – OPMI PENTERO 900 
Microscope and fluorescent screenshot reproduced with permission from Carl Zeiss 
Ltd, mouse computed tomography (CT) [96], mouse single-photon emission 
computed tomography (SPECT) [97], human single-photon emission computed 
tomography (SPECT) [98], human positron emission tomography (PET) [99], mouse 
positron emission tomography (PET) [100]. Advantages and limitations of each 
imaging modality are highlighted. 
 
Figure 2 DCE-MRI used to assess the potential efficacy of various GBM 
therapies in individual patients  
The image shows a distinct decrease in volume transfer constant (Ktrans) and 
increase in microvessel cerebral blood volume (CBV). It was associated with high 
survival rates (A), compared to low survival rates in the patient with little change in 
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Ktrans and microvessel CBV (B). “Vascular normalization index” values obtained from 
DCE-MRI provide indication of progression-free survival (PFS) (C) and overall 
survival (OS) (D) in patients treated once with the angiogenesis inhibitor cediranib. 
Image adapted from Sorensen et al., 2009 [47] 
 
 
Figure 3 PET used to assess the potential efficacy of mTOR inhibitors  
The figure shows 18F-fluorodeoxyglucose- (18F-FDG) and 3′-18F-fluoro-3′-
deoxythymidine- (18F-FLT) positron emission tomography (PET)/ computed 
tomography (CT) scans of U87 and LN-229 xenografts before and after one dosage 
of rapamycin (3 mg/kg). Axial 18F-FDG PET/ CT scans of representative tumour are 
shown in (A) and (B). Changes in tumour 18F-FDG uptake are summarized in (C) 
and (D). 18F-FLT PET scans of representative tumour are shown in (E) and (F). 
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Changes in tumour 18F-FLT uptake are summarized in (G) and (H). Figure adopted 
from Wei et al., 2008 [67] 
 
Figure 4 Discrepancy between post-therapeutic image changes on MRI and 
11C-MET PET scans  
Images in (A) and (B) represent the treatment planning at two distinct levels of the 
tumour. T1-weighted magnetic resonance imaging (MRI) and 11C-methionine 
positron emission tomography (11C-MET PET) scans were fused with intraoperative 
stereotactic computed tomography images. The same procedure was performed with 
follow-up data taken 8 weeks after intra-tumoural infusion of LIPO-HSV-1-tk (C, D). 
The position of the two infusion catheters is indicated (red cross) and baseline 
extension of the tumour is outlined (blue dotted line: summarized information from 
T1- and T2-weighted series; yellow dotted line: 11C-MET PET scans). Eight weeks 
after intra-tumoural infusion of LIPO-HSV-1-tk, 11C-MET PET scans displayed a 50 
% reduction of the tumour volume if compared with baseline (Patient 3). In contrast, 
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the volume of gadolinium with diethylenetriaminepentaacetic acid (Gd-DTPA) uptake 
was increased by 300 % most likely due to gene therapy-induced alteration of blood–
brain barrier (BBB). Figure adopted from Voges et al, 2003 [82] 
 
Figure 5 The tumour initiation and maintenance potential of GSCs is reduced 
by NOS2 inhibition  
Luciferase-expressing GBM stem cells (GSC)-derived intracranial xenografts were 
treated with intraperitoneal vehicle or BYK191023 (n = 17 per group) after 
engraftment and tracked by bioluminescence imaging (BLI). Real-time images from 
median three animals on day 9 are shown (right). Mean tumour bioluminescence 
signal for each group over time is shown (left). *p < 0.05. Error bars represent the 
mean ± SEM of the indicated number of animals. Figure adopted from Eyler et al., 
2011 [87] 
 
50 
 
Table legend 
Table 1. Application of preclinical and clinical molecular imaging strategies in 
brain tumours  
MI Main applications Ref 
M
R
I 
T1-weighted   Anatomical investigations (e.g. tumour location, 
volume) 
 Pathological investigations (e.g. assessment of blood 
brain barrier function) when combined with contrast 
enhancement 
[5] 
T2-weighted  Pathological investigations (e.g. visualisation of 
oedema, accumulation of cerebral spinal fluid) 
[5] 
1H-MRS  Detection of tumour cell infiltration [9] 
DSC  Measures rCBV 
 Monitoring of tumour response to anti-angiogenic 
treatment 
[45] 
DCE  Measures Ktrans 
 Monitoring of tumour response to anti-angiogenic 
treatment  
[46] 
ASL  Measures CBF 
 Monitoring of tumour response to anti-angiogenic 
treatment 
[97] 
DW  Identification of tumour grade 
 Assessment of tumour cell infiltration 
[13] 
DT  Detection of tumour cell invasion 
 Pre-operative planning of tumour removal 
[98] 
BOLD-fMRI  Localisation of eloquent brain regions 
 Pre-operative planning of tumour removal 
[15] 
P
ET
 
18F-FDG  Glucose metabolism 
 Tumour visualization 
[17] 
18F-FLT  Assessment of tumour proliferation rate 
 Assessment of therapy response 
[20] 
18F-MET  Amino acid transport/ protein synthesis 
 Assessment of tumour size 
 Detection of post-therapeutic changes (e.g. radiation 
[18] 
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necrosis, oedema) 
18F-FET  Amino acid transport/ protein synthesis 
 Detection of recurrent tumour and biopsy site 
 Assessment of tumour location and extent 
[19] 
11C-CHO  Tumour detection and grading [17] 
18F-FMISO  Assessment of tumour hypoxia [21] 
18F-Fluciclatide  Assessment of αvβ3 and αvβ5 integrins expression [22] 
18F- Galacto-RGD  Assessment of αvβ3 integrin expression [99] 
SP
EC
T 
201Tl  Tumour detection [24] 
99mTc-MIBI  Assessment of tumour progression and grading [25] 
123IMT  Differentiation between tumour recurrence, radiation 
necrosis and oedema 
[26] 
O
p
ti
ca
l 
BLI  Tumour localisation 
 Tumour progression 
 Treatment response 
[28] 
Fluorescence  Tumour localisation 
 Tumour progression 
 Treatment response 
[30] 
Photodynamic 
navigation 
 Visual recognition of tumour tissue during surgical 
resection 
[31] 
 
(Abbreviations: 1H-MRS - proton magnetic resonance spectroscopy, MRI - magnetic 
resonance imaging, DSC - dynamic susceptibility contrast, ASL - arterial spin labelling, DW 
- diffusion-weighted, DT - diffusion tensor, BOLD-fMRI - blood oxygenation level 
dependent functional magnetic resonance imaging, PET – positron emission 
tomography, 18F-FDG - 18F-fluorodeoxyglucose, 18F-FLT - 3′-18F-fluoro-3′-
deoxythymidine, 11C-MET - 11C-methionine, 18F-FET - O-(2-18F-fluoroethyl)-L-
tyrosine, 11C-CHO - 11C-choline, 18F-FMISO - 18F-fluoromisonidazole, 18F-
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Galacto-RGD – 18F-galacto-arginine-glycine-aspartic acid, SPECT - single photon 
emission computed tomography, 201Tl - thallium-201, 123IMT - iodine-123-alpha-
methyl-tyrosine, BLI – bioluminescence imaging) 
Class Drug Target MI Ref 
A
n
gi
o
ge
n
es
is
 In
h
ib
it
o
rs
 
Bevcizumab VEGF-A 
DW-MRI 
FLT-PET 
[49,51] 
Sunitinib 
VEGF-R 
PDGF-R 
RTKs (KIT, RET, CSF-1R, flt3) 
18F-Fluciclatide-PET [22] 
Cediranib VEGF 
DCE-MRI 
DW-MRI 
[13,46] 
Enzastaurin VEGF DSC-MRI [45] 
EG
FR
 In
h
ib
it
o
rs
 Cetuximab EGFR BLI [58] 
Ch806 EGFR immuno-PET [60] 
m
T
O
R
 In
h
ib
it
o
rs
 
Rapamycin 
mTOR 
FRAP1 
[18F] FDG-PET 
[18F] FLT-PET 
[66] 
CCI 779 
mTOR 
FRAP1 
MRI [69] 
Everolimus mTOR 13C MRI [67] 
St
e
m
 
ce
ll 
ap
p
ro
ac
h
 BYK191023 NOS2 BLI [86] 
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GSI-18 γ-secretase inhibitor MRI [87] 
 
 
Table 2. Examples of molecular imaging approaches used in development of 
anti-GBM therapies  
(Abbreviations: VEGF – vascular endothelial growth factor; R – receptor; PDGF – 
platelet derived growth factor; RTK – receptor tyrosine kinase; PKCβ – protein kinase 
C beta; PI3-K – phosphatidylinositol 3-kinase; EGF – epidermal growth factor; NOS2 
– nitric oxide synthase 2; mTOR – mammalian target of rapamycin; FRAP-1 – FK506 
binding protein 12-rapamycin associated protein 1; MRI – magnetic resonance 
imaging; DW – diffusion weighted; DCE – dynamic contrast enhanced; DSC – 
dynamic susceptibility contrast; PET – positron emission tomography; FLT – fluoro-
3‟-deoxy-L-thymidine; F – fluorine; FDG – fluorine-2-deoxy-D-glucose; BLI – 
bioluminescence imaging)  
 
